Please login to the form below

Not currently logged in
Email:
Password:

Metrics appoints director of pharma development

Promotion for Joseph Cobb at contract development and manufacturing organisation

Joseph Cobb has been named as the director of pharmaceutical development at the US contract development and manufacturing company Metrics.

The appointment is a promotion for Cobb, who has been with North Carolina-based Metrics since 2002, serving most recently as associate director of pharmaceutical development.

In his new role, Cobb will oversee Metrics' work in early-phase solid oral dosage development, as well as the company's potent and cytotoxic drug development services.

These services cover pharmaceutical formulation development; first-time- in-man formulations; and the manufacturing of clinical materials for trials covering phase I to III.

“Joe is a smart and capable leader who has been instrumental in guiding the success and growth of Metrics' formulation development capabilities,” said Phil Hodges, president of the company, which operates as a subsidiary of Mayne Pharma.

“With these new responsibilities, Joe will bring to his role the same thoughtfulness and resourcefulness.”

7th February 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Stick or Twist? Healthcare brands in a (post) COVID-19 world
...